MYGN
Myriad Genetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.19
−1.24%Margins
Gross margin
68.8%
EBITDA margin
-5.6%
EBIT margin
-12.2%
Net margin
-14.0%
FCF margin
-1.1%
-37.1%
Return on equity
-17.6%
Return on assets
-19.2%
Return on invested capital
1.23x
Asset turnover
$7.7M
Cash from operations
$1.20
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026